MedPath

武汉五景药业有限公司

Ownership
-
Established
2001-12-30
Employees
-
Market Cap
-
Website
www.wjyy.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

84

NMPA:84

Drug Approvals

Diquafosol Sodium Eye Drops

Product Name
地夸磷索钠滴眼液
Approval Number
国药准字H20253766
Approval Date
Apr 1, 2025
NMPA

Bromfenac Sodium Eye Drops

Product Name
溴芬酸钠滴眼液
Approval Number
国药准字H20244284
Approval Date
Jun 28, 2024
NMPA

Ofloxacin Ea rDrops

Product Name
氧氟沙星滴耳液
Approval Number
国药准字H20083329
Approval Date
Feb 3, 2023
NMPA

Stavudine

Product Name
司他夫定
Approval Number
国药准字H20060881
Approval Date
Apr 13, 2021
NMPA

Phacolysin

Product Name
法可林
Approval Number
国药准字H42022729
Approval Date
Jul 8, 2020
NMPA

Compound Sulfamethoxazole Tablets

Product Name
复方磺胺甲噁唑片
Approval Number
国药准字H42021095
Approval Date
Jul 8, 2020
NMPA

Naphazoline Hydrochloride Eye Drops

Product Name
盐酸萘甲唑啉滴眼液
Approval Number
国药准字H20054990
Approval Date
Jul 8, 2020
NMPA

Pilocarpine Nitrate Eye Drops

Product Name
硝酸毛果芸香碱滴眼液
Approval Number
国药准字H20023807
Approval Date
Jul 8, 2020
NMPA

Chlorzoxazone Tablets

Product Name
氯唑沙宗片
Approval Number
国药准字H42022720
Approval Date
Jul 8, 2020
NMPA

Amiodarone Hydrochloride Tablets

Product Name
盐酸胺碘酮片
Approval Number
国药准字H42021103
Approval Date
Jul 8, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 9
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.